Comparative Pharmacology
Head-to-head clinical analysis: ADHANSIA XR versus ADZENYS ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADHANSIA XR versus ADZENYS ER.
ADHANSIA XR vs ADZENYS ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adhansia XR is a central nervous system (CNS) stimulant. The mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully known, but it is thought to involve blockade of norepinephrine and dopamine reuptake into presynaptic neurons, increasing their levels in the synaptic cleft. This enhances attention and reduces impulsivity.
ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Methylphenidate hydrochloride extended-release: Oral, 18-72 mg once daily in the morning.
Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.
None Documented
None Documented
Mean terminal elimination half-life is 7.5 hours (range 5-10 hours) following oral administration, allowing twice-daily dosing.
6-8 hours in adults; in children 3-6 hours, requiring twice-daily dosing for sustained effect
Primarily renal (78% as unchanged drug), with 10% biliary/fecal elimination.
70% renal (30% unchanged, 40% as metabolites), 30% fecal/biliary
Category C
Category C
CNS Stimulant
CNS Stimulant